SCOTS patients affected by advanced skin cancer will now have access to a drug that could help keep the disease at bay for longer.

Nivolumab (Opdivo) was approved for the treatment of advanced melanoma, which may prevent a recurrence or lengthen the time before the cancer returns.

Currently at this stage of the condition, patients have routine checks and scans at clinic but there is no active treatment available to help prevent or delay a recurrence.

The disease claimed the life of Celtic legend Tommy Burns.

Pertuzumab (Perjeta), which is used in combination with trastuzumab and chemotherapy to treat a particular type of breast cancer at an early stage and prior to surgery, was approved by the Scottish Medicines Consortium.

The treatment may reduce the risk of recurrence and offer improved chance of longer term survival.

Ocrelizumab (Ocrevus) was also accepted for treatment of relapsing remitting multiple sclerosis (MS).

Those with relapsing remitting MS experience periods when symptoms flare up (relapsing) followed by periods of good or complete recovery (remitting). Ocrelizumab may help reduce both the rate of relapses and the progression of disability.

Dr Alan MacDonald, SMC Chairman, said:“I am pleased the committee has been able to accept pertuzumab for the treatment of early stage breast cancer prior to surgery.

“Nivolumab offers a treatment for patients currently relying on a “watch and wait” approach to monitor their melanoma. Having the reassurance of a treatment that may give them more time will support those at this stage of the condition.”

“For those with relapsing remitting MS, ocrelizumab is a useful addition to the range of disease modifying therapies that can be used to treat their condition.”